These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 23732650)

  • 1. A new selective vascular endothelial growth factor receptor 2 inhibitor ablates disease in a mouse model of psoriasis.
    Yan HX; Wang Y; Yang XN; Fu LX; Tang DM
    Mol Med Rep; 2013 Aug; 8(2):434-8. PubMed ID: 23732650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
    Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
    Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant murine interleukin 4 protein therapy for psoriasis in a transgenic VEGF mouse model.
    Ren X; Li J; Zhou X; Luo X; Huang N; Wang Y; Chen X; Wei Y
    Dermatology; 2009; 219(3):232-8. PubMed ID: 19729876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gambogic acid exhibits anti-psoriatic efficacy through inhibition of angiogenesis and inflammation.
    Wen J; Pei H; Wang X; Xie C; Li S; Huang L; Qiu N; Wang W; Cheng X; Chen L
    J Dermatol Sci; 2014 Jun; 74(3):242-50. PubMed ID: 24685902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TPA induction leads to a Th17-like response in transgenic K14/VEGF mice: a novel in vivo screening model of psoriasis.
    Hvid H; Teige I; Kvist PH; Svensson L; Kemp K
    Int Immunol; 2008 Aug; 20(8):1097-106. PubMed ID: 18579711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SKLB1002, a potent inhibitor of VEGF receptor 2 signaling, inhibits endothelial angiogenic function in vitro and ocular angiogenesis in vivo.
    Zhang QY; Tao SY; Lu C; Li JJ; Li XM; Yao J; Jiang Q; Yan B
    Mol Med Rep; 2020 Jun; 21(6):2571-2579. PubMed ID: 32323773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VEGF and angiogenesis in acute and chronic MOG((35-55)) peptide induced EAE.
    Roscoe WA; Welsh ME; Carter DE; Karlik SJ
    J Neuroimmunol; 2009 Apr; 209(1-2):6-15. PubMed ID: 19233483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic ALA-PDT effectively blocks the development of psoriasis-like lesions and alleviates leucocyte infiltration in the K14-VEGF transgenic mouse.
    Chen T; Zhang LW; Fu LX; Wu YB; Liu XY; Guo ZP
    Clin Exp Dermatol; 2017 Dec; 42(8):849-856. PubMed ID: 28597992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical, pathological and immunological features of psoriatic-like lesions affecting keratin 14-vascular endothelial growth factor transgenic mice.
    Canavese M; Altruda F; Silengo L; Castiglioni V; Scanziani E; Radaelli E
    Histol Histopathol; 2011 Mar; 26(3):285-96. PubMed ID: 21210341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular endothelial growth factor receptor-2 inhibition in experimental murine colitis.
    Knod L; Donovan EC; Chernoguz A; Crawford KM; Dusing MR; Frischer JS
    J Surg Res; 2013 Sep; 184(1):101-7. PubMed ID: 23688787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
    Wiedmann M; Feisthammel J; Blüthner T; Tannapfel A; Kamenz T; Kluge A; Mössner J; Caca K
    Anticancer Drugs; 2006 Aug; 17(7):783-95. PubMed ID: 16926628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis--a possible target for novel therapies?
    Canavese M; Altruda F; Ruzicka T; Schauber J
    J Dermatol Sci; 2010 Jun; 58(3):171-6. PubMed ID: 20430590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A selective and oral small molecule inhibitor of vascular epithelial growth factor receptor (VEGFR)-2 and VEGFR-1 inhibits neovascularization and vascular permeability.
    Patel N; Sun L; Moshinsky D; Chen H; Leahy KM; Le P; Moss KG; Wang X; Rice A; Tam D; Laird AD; Yu X; Zhang Q; Tang C; McMahon G; Howlett A
    J Pharmacol Exp Ther; 2003 Sep; 306(3):838-45. PubMed ID: 12766257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ginsenoside Rh2 Suppresses Neovascularization in Xenograft Psoriasis Model.
    Zhou J; Gao Y; Yi X; Ding Y
    Cell Physiol Biochem; 2015; 36(3):980-7. PubMed ID: 26087848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VEGF-C and VEGF-D blockade inhibits inflammatory skin carcinogenesis.
    Alitalo AK; Proulx ST; Karaman S; Aebischer D; Martino S; Jost M; Schneider N; Bry M; Detmar M
    Cancer Res; 2013 Jul; 73(14):4212-21. PubMed ID: 23695550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
    Huh JI; Calvo A; Stafford J; Cheung M; Kumar R; Philp D; Kleinman HK; Green JE
    Oncogene; 2005 Jan; 24(5):790-800. PubMed ID: 15592523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tracking adult neovascularization during ischemia and inflammation using Vegfr2-LacZ reporter mice.
    Heidenreich R; Murayama T; Silver M; Essl C; Asahara T; Rocken M; Breier G
    J Vasc Res; 2008; 45(5):437-44. PubMed ID: 18418002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphoinositide 3-kinase-delta inhibitor reduces vascular permeability in a murine model of asthma.
    Lee KS; Park SJ; Kim SR; Min KH; Jin SM; Puri KD; Lee YC
    J Allergy Clin Immunol; 2006 Aug; 118(2):403-9. PubMed ID: 16890765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.